LONDON: European private equity fund PAI Partners is to buy French drugmaker Ethypharm for about 750 million euros ($855 million) from fellow private equity firm Astorg, two sources with knowledge of the matter said on Friday.
PAI has trumped rival bids from Bain Capital and European pharmaceutical firm Mundipharma, the sources said.
The sale, led by Rothschild, values the business at more than 12 times its 2015 earnings before interest, taxes, depreciation and amortization (EBITDA) of 60 million euros, the sources said. PAI Partners and Astorg were not immediately available for comment.
Based in Saint-Cloud, near Paris, Ethypharm does business in 30 countries and employs about 830 people. Last year it expanded in Britain with the acquisition of off-patent pharmaceuticals provider DB Ashbourne.
Ethypharm specializes in pain and addiction treatment, and also provides generic drugs to treat stomach and intestinal problems, as well as cardiovascular diseases.
Walmart on Gateway Boulevard West in El Paso.— Google MapsNow that US interest rates seem to have stabilised, there...
Boats float on the river Nile in Cairo, April 30, 2013. — ReutersCAIRO: Egypt appears on track to break with past...
A man selling vegetables waits for customers at his makeshift stall at Empress Market in Karachi. — ReutersLAHORE:...
A woman shops in a wet market in Kuala Lumpur, Malaysia, February 18, 2016. — REUTERSKUALA LUMPUR: Malaysia's...
The Pakistan Business Forum logo. — Facebook/pbf.limitedISLAMABAD: The Pakistan Business Forum on Saturday called...
US dollar banknotes are seen in this illustration taken March 10, 2023. — REUTERSKARACHI: The government plans to...